Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 34
- Registration Number
- NCT01943513
- Locations
- 🇺🇸
Research Site, Evansville, Indiana, United States
Ireland Natalizumab (TYSABRI) Observational Program
- Conditions
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 191
- Registration Number
- NCT01943526
- Locations
- 🇮🇪
Research site, Sligo, County Sligo, Ireland
Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 251
- Registration Number
- NCT01939002
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 87
- Registration Number
- NCT01930890
- Locations
- 🇹🇭
Research Site, Pathumwan, Bangkok, Thailand
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
- Conditions
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1114
- Registration Number
- NCT01930708
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Daclizumab Japanese PK Study
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 56
- Registration Number
- NCT01929746
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
BG00012 Regional Absorption Study
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 32
- Registration Number
- NCT01924832
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 101
- Registration Number
- NCT01917019
- Locations
- 🇯🇵
Research Site, Yachiyo-shi, Japan
PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily
- Conditions
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2014-03-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 175
- Registration Number
- NCT01915901
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Biogen Multiple Sclerosis Pregnancy Exposure Registry
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 408
- Registration Number
- NCT01911767
- Locations
- 🇬🇧
Research Site, Salford, Greater Manchester, United Kingdom